← Back to Clinical Trials
Recruiting NCT05991037

NCT05991037 Relation Between Psychoactive Drugs Overdosage and Severity of Falls in Elderly People

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05991037
Status Recruiting
Phase
Sponsor University Hospital, Caen
Condition Fall
Study Type INTERVENTIONAL
Enrollment 400 participants
Start Date 2024-05-22
Primary Completion 2027-05-30

Eligibility & Interventions

Sex All sexes
Min Age 75 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Blood sampling for psychoactive drugs dosage

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 400 participants in total. It began in 2024-05-22 with a primary completion date of 2027-05-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

There are many epidemiological data on the relationship between the number or nature of psychoactive medications used and the risk of falling in elderly, but very little on the relationship between the amount of psychoactive medication actually present in the blood and the severity of the fall. However, the inevitable drug-drug interactions related to polypharmacy and the pharmacokinetic modifications related to old age may lead plasma overdose situations which can potentiate the risk of falls but also aggravate these consequences. The investigators therefore propose a study with the objective of verifying whether the proportion of falls with serious traumatic consequences is more frequent in patients over 75 years old, presenting plasma overdoses of psychoactive drugs (plasma concentrations higher than the usual therapeutic concentrations) in regard to those between therapeutic ranges. The aim of this work is to verify if the falls present more severe characters when the psychoactive drug concentrations are beyond the usual therapeutic ranges.

Eligibility Criteria

Inclusion Criteria: * Patient (male, female) aged 75 and over admitted to the emergency room for a fall and for whom hospitalization (in geriatrics or not) after going to the emergency room is planned * Patient consuming at least one psychoactive drug from the list provided in the protocol * Patient able to move before hospitalization with or without technical assistance * Patient who signed the consent * Patient subject to the social security system Exclusion Criteria: * Patient not requiring hospitalization after going to the emergency room * Patient having fallen for more than 12 hours before inclusion in the study (time of sampling) \[risk of excessive elimination of certain drugs with short half-lives\] * Parkinsonian patient or patient who has fallen following a convulsive attack * Patient with a life-threatening prognosis in the very short term (state of shock, palliative care planned from the emergency room) * Patient in wheelchair or bedridden * Adult under legal protection, guardianship, curators * Patient not understanding the French language

Contact & Investigator

Central Contact

Véronique Lelong-Boulouard, PhD

✉ lelongboulouard-v@chu-caen.fr

📞 0231063341

Principal Investigator

Véronique Lelong-Boulouard, PhD

STUDY DIRECTOR

Caen Normandie Universitary Hospital Center

Frequently Asked Questions

Who can join the NCT05991037 clinical trial?

This trial is open to participants of all sexes, aged 75 Years or older, studying Fall. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05991037 currently recruiting?

Yes, NCT05991037 is actively recruiting participants. Contact the research team at lelongboulouard-v@chu-caen.fr for enrollment information.

Where is the NCT05991037 trial being conducted?

This trial is being conducted at Caen, France.

Who is sponsoring the NCT05991037 clinical trial?

NCT05991037 is sponsored by University Hospital, Caen. The principal investigator is Véronique Lelong-Boulouard, PhD at Caen Normandie Universitary Hospital Center. The trial plans to enroll 400 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology